Hot Life Science Investor Mandate 1: Corporate Venture Capital Firm Seeking Pre-Clinical Stage Novel Platform Therapeutics

5 Mar

A large European pharmaceutical company recently opened a US office to invest out of a $130 million evergreen corporate venture fund. The fund is interested in life science opportunities globally, and expects to make 3-4 new investments per year. The fund typically invests about $10 million over the life of an investment.  The fund is typically a lead investor, and participates in syndicates with other investment firms.

The fund seeks to invest in companies with preclinical assets.  The firm prefers to invest in companies developing therapeutic platform technologies.  The fund is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, gene therapy and regenerative medicine are particularly of interest.  The fund is focused on investing in oncology, but will also consider opportunities in other indication areas.

The fund invests in technologies of strategic importance to its parent company. The fund only invests in privately held companies.  The fund typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: